|
US2011A
(en)
|
|
1841-03-18 |
|
Appabatxts for piling saws |
|
US154516A
(en)
|
|
1874-08-25 |
|
Improvement in pistons for steam-engines |
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US3941763A
(en)
|
1975-03-28 |
1976-03-02 |
American Home Products Corporation |
PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
FR2560212B1
(fr)
|
1984-02-24 |
1989-12-29 |
Unicet |
Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
|
US5453269A
(en)
|
1986-04-14 |
1995-09-26 |
The General Hospital Corporation |
Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5559212A
(en)
|
1988-04-06 |
1996-09-24 |
Alfacell Corporation |
Frog embryo and egg-derived tumor cell anti-proliferation protein
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
IL88377A
(en)
|
1988-11-14 |
1996-09-12 |
Yeda Res & Dev |
Cloning and expression of a protein which modulates cellular response to type I interferon
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
FR2653445B1
(fr)
|
1989-10-20 |
1994-07-29 |
Centre Nat Rech Scient |
Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
|
|
US5889151A
(en)
|
1989-10-20 |
1999-03-30 |
Societe Leb-Tech |
Purified human alpha interferon receptor
|
|
US5840840A
(en)
|
1990-04-17 |
1998-11-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Selective RNase cytotoxic reagents
|
|
US5525491A
(en)
|
1991-02-27 |
1996-06-11 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
|
EP0537166B1
(fr)
|
1991-04-17 |
1999-07-07 |
Medisup International N.V. |
Polypeptides hydrosolubles ayant une haute affinite pour les interferons alpha et beta
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5994514A
(en)
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
JPH06510061A
(ja)
|
1991-08-30 |
1994-11-10 |
ジェネンテク，インコーポレイテッド |
Ｉｄｄｍの治療法
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
|
EP0563487A1
(en)
|
1992-03-31 |
1993-10-06 |
Laboratoire Europeen De Biotechnologie S.A. |
Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
|
|
EP0671926B1
(en)
|
1992-08-11 |
2002-11-13 |
President And Fellows Of Harvard College |
Immunomodulatory peptides
|
|
US5423269A
(en)
|
1992-11-24 |
1995-06-13 |
Gunderson, Inc. |
Railroad well car body including side sill reinforcing walkway structure
|
|
GB9300686D0
(en)
|
1993-01-15 |
1993-03-03 |
Imp Cancer Res Tech |
Compounds for targeting
|
|
US20030108548A1
(en)
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
IL107378A
(en)
|
1993-10-24 |
2005-05-17 |
Yeda Res & Dev |
SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US6348343B2
(en)
|
1995-02-24 |
2002-02-19 |
Genentech, Inc. |
Human DNase I variants
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5780027A
(en)
|
1995-07-14 |
1998-07-14 |
Meiogen Biotechnology Corporation |
Methods of treatment of down syndrome by interferon antagonists
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
US6482626B2
(en)
|
1996-02-05 |
2002-11-19 |
Genentech, Inc. |
Human DNase
|
|
US6716974B1
(en)
|
1996-05-31 |
2004-04-06 |
Maine Medical Center Research Institute |
Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
|
|
US6391607B1
(en)
|
1996-06-14 |
2002-05-21 |
Genentech, Inc. |
Human DNase I hyperactive variants
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
US7247302B1
(en)
|
1996-08-02 |
2007-07-24 |
Bristol-Myers Squibb Company |
Method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
ES2191827T3
(es)
|
1996-10-17 |
2003-09-16 |
Immunomedics Inc |
Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020132252A1
(en)
|
1997-06-16 |
2002-09-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20020192659A1
(en)
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US6280991B1
(en)
|
1997-10-15 |
2001-08-28 |
Wisconsin Alumni Research Foundation |
Engineered cytotoxic ribonclease
|
|
US5840296A
(en)
|
1997-10-15 |
1998-11-24 |
Raines; Ronald T. |
Engineered cytotoxic ribonuclease A
|
|
PL197568B1
(pl)
|
1997-12-19 |
2008-04-30 |
Applied Research Systems |
Kompleks zawierający IFN typu I oraz podjednostkę IFNAR, jego zastosowanie, cząsteczka DNA i wektor ją zawierający, komórka gospodarza transformowana wektorem, kompozycja farmaceutyczna, lek, zastosowanie IFNAR, zastosowanie IFN typu I i podjednostki IFNAR, sposób wytwarzania białka fuzyjnego oraz sposób przedłużania okresu trwałości IFN
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US20030175778A1
(en)
|
1998-06-05 |
2003-09-18 |
Jian Ni |
Interferon Receptor HKAEF92
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
AU2342900A
(en)
|
1998-09-23 |
2000-05-01 |
Cleveland Clinic Foundation, The |
Novel interferon stimulated and repressed genes
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
AUPP670698A0
(en)
|
1998-10-23 |
1998-11-19 |
Monash University |
A method of regulation
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6239257B1
(en)
|
1998-12-30 |
2001-05-29 |
Alfacell Corporation |
Family of proteins belonging to the pancreatic ribonuclease a superfamily
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
EP1194451A1
(en)
|
1999-07-02 |
2002-04-10 |
Genentech, Inc. |
Fusion peptides comprising a peptide ligand domain and a multimerization domain
|
|
US6175003B1
(en)
|
1999-09-10 |
2001-01-16 |
Alfacell Corporation |
Nucleic acids encoding ribonucleases and methods of making them
|
|
US7118751B1
(en)
|
1999-10-14 |
2006-10-10 |
Trubion Pharmaceuticals, Inc. |
DNA vaccines encoding antigen linked to a domain that binds CD40
|
|
AU2001257001A1
(en)
|
2000-04-10 |
2001-10-23 |
Mount Sinai School Of Medicine Of New York University |
Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
|
|
US7029872B2
(en)
|
2000-06-28 |
2006-04-18 |
Glycofi, Inc |
Methods for producing modified glycoproteins
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
JP4394350B2
(ja)
|
2001-01-09 |
2010-01-06 |
ベイラー リサーチ インスティテュート |
対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
AU2002327164A1
(en)
|
2001-01-29 |
2002-12-09 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
|
BR0206985A
(pt)
|
2001-01-29 |
2005-04-19 |
Idec Pharma Corp |
Anticorpos modificados e métodos de uso
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
DK1366067T3
(da)
|
2001-03-07 |
2012-10-22 |
Merck Patent Gmbh |
Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
|
|
JP4586310B2
(ja)
|
2001-07-04 |
2010-11-24 |
株式会社Ihi |
セラミックス複合部材の製造方法
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US20060040262A1
(en)
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
|
IL147414A0
(en)
|
2001-12-31 |
2002-08-14 |
Yeda Res & Dev |
Ifnar2 mutants, their production and use
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
WO2003097877A1
(fr)
|
2002-05-17 |
2003-11-27 |
Riken |
Procede de detection d'un polymorphisme genique
|
|
CA2489446A1
(en)
|
2002-06-14 |
2003-12-24 |
Wisconsin Alumni Research Foundation |
Ribonuclease zymogen design
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
AU2003284357A1
(en)
|
2002-11-01 |
2004-06-07 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US7067298B2
(en)
|
2003-03-31 |
2006-06-27 |
Ambion, Inc. |
Compositions and methods of using a synthetic Dnase I
|
|
US7666417B2
(en)
|
2003-04-22 |
2010-02-23 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for treating autoimmune diseases or conditions
|
|
CA2522957C
(en)
|
2003-04-23 |
2013-10-22 |
Medarex, Inc. |
Compositions and methods for the therapy of inflammatory bowel disease
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040266993A1
(en)
|
2003-06-30 |
2004-12-30 |
Evans Glen A. |
Non-immunoglobulin binding polypeptides
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
CA2541523A1
(en)
|
2003-10-21 |
2005-05-06 |
Applied Research Systems Ars Holding N.V. |
Minimal dna sequence acting as a chromatin insulator and its use in protein expression
|
|
HUE038955T2
(hu)
|
2003-11-05 |
2018-12-28 |
Roche Glycart Ag |
Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
EP1699821B1
(en)
|
2003-12-31 |
2012-06-20 |
Merck Patent GmbH |
Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
JP5150103B2
(ja)
|
2004-02-13 |
2013-02-20 |
イミューノメディクス、インコーポレイテッド |
組み換え細胞毒性ＲＮＡｓｅを含む融合タンパク質
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
KR20070041781A
(ko)
|
2004-08-11 |
2007-04-19 |
트루비온 파마슈티칼스, 인코포레이티드 |
결합 도메인 융합 단백질
|
|
JP2006071409A
(ja)
|
2004-09-01 |
2006-03-16 |
Kansai Tlo Kk |
シェーグレン症候群診断キット
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
NZ554065A
(en)
|
2004-10-07 |
2010-12-24 |
Univ Zuerich |
Use of an anti-interferon-alpha antibody for prevention and treatment of psoriasis
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
DE102005009219A1
(de)
|
2005-02-25 |
2006-08-31 |
Martin-Luther-Universität Halle-Wittenberg |
Ribonuclease-Tandemenzyme und Verfahren zu ihrer Herstellung
|
|
US20110123440A1
(en)
|
2005-03-29 |
2011-05-26 |
Genevieve Hansen |
Altered Antibody FC Regions and Uses Thereof
|
|
EP1888649A2
(en)
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
|
DE602006017705D1
(de)
|
2005-06-16 |
2010-12-02 |
Wisconsin Alumni Res Found |
Zytotoxische ribonukleasevarianten
|
|
WO2006138558A2
(en)
|
2005-06-16 |
2006-12-28 |
Wisconsin Alumni Research Foundation |
Cytotoxic ribonuclease variants
|
|
US7732167B2
(en)
|
2005-06-17 |
2010-06-08 |
Regeneron Pharmaceuticals, Inc. |
Interferon-α/β binding fusion proteins and therapeutic uses thereof
|
|
US20080279850A1
(en)
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
AU2006272555B2
(en)
|
2005-07-25 |
2012-03-08 |
Aptevo Research And Development Llc |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
US7608395B2
(en)
|
2005-09-15 |
2009-10-27 |
Baylor Research Institute |
Systemic lupus erythematosus diagnostic assay
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
WO2007045465A1
(en)
|
2005-10-21 |
2007-04-26 |
F. Hoffmann-La Roche Ag |
Method for the recombinant expression of a polypeptide
|
|
US7892740B2
(en)
|
2006-01-19 |
2011-02-22 |
The University Of Chicago |
Prognosis and therapy predictive markers and methods of use
|
|
DK1999154T3
(da)
|
2006-03-24 |
2012-12-03 |
Merck Patent Gmbh |
Fremstillede heterodimere proteindomæner
|
|
EP2007808A4
(en)
|
2006-04-14 |
2010-07-21 |
Trubion Pharmaceuticals Inc |
BINDING PROTEINS HAVING AN IMMUNOGLOBULIN HINGE AND FC REGIONS WITH ALTERED EFFECTOR FUNCTIONS
|
|
EP2010221B1
(en)
|
2006-04-21 |
2012-02-29 |
mAB-Factory GmbH |
Antibody-rnase-conjugate
|
|
WO2007136789A2
(en)
|
2006-05-19 |
2007-11-29 |
Medimmune, Inc. |
Methods of preventing, treating or ameliorating enhanced respiratory disease via innate immune mechanisms
|
|
GB0611444D0
(en)
|
2006-06-09 |
2006-07-19 |
Medical Res Council Technology |
Rnase H2 complex and genes therefor
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
DK2046826T3
(da)
|
2006-07-24 |
2011-10-24 |
Biorexis Pharmaceutical Corp |
Exendin-fusionsproteiner
|
|
US8198063B1
(en)
|
2006-09-12 |
2012-06-12 |
Pro Zyme, Inc |
Rapid deglycosylation of glycoproteins
|
|
EP1905841A1
(en)
|
2006-09-25 |
2008-04-02 |
Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; |
Trex1 as a marker for lupus erythematosus
|
|
US8277797B2
(en)
|
2006-11-22 |
2012-10-02 |
The Regents Of The University Of California |
Interferon-β production modulating Listeria strains and methods for using same
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
WO2008137838A2
(en)
|
2007-05-03 |
2008-11-13 |
Medimmune, Llc |
Interferon alpha-induced pharmacodynamic markers
|
|
MX2009012343A
(es)
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
US20090258005A1
(en)
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
CN101842389A
(zh)
|
2007-06-12 |
2010-09-22 |
惠氏有限责任公司 |
抗cd20治疗组合物和方法
|
|
WO2009023386A2
(en)
|
2007-07-06 |
2009-02-19 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
|
WO2009015345A1
(en)
|
2007-07-25 |
2009-01-29 |
Amgen Inc. |
Pharmaceutical compositions comprising fc fusion proteins
|
|
US8067548B2
(en)
|
2007-07-26 |
2011-11-29 |
Novagen Holding Corporation |
Fusion proteins having mutated immunoglobulin hinge region
|
|
AU2008311973B2
(en)
|
2007-10-15 |
2013-10-03 |
Cangene Corporation |
Human Factor IX variants with an extended half life
|
|
EP2220125A4
(en)
|
2007-11-13 |
2010-12-29 |
Sapphire Energy Inc |
PRODUCTION OF FC HYBRID POLYPEPTIDES IN EUKARYOTIC ALGAE
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
|
EP2300501B1
(en)
|
2008-07-23 |
2014-08-20 |
Hanmi Science Co., Ltd. |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
|
JP2012503985A
(ja)
|
2008-09-26 |
2012-02-16 |
ジェネンテック， インコーポレイテッド |
ループスの治療、診断、モニタリング方法
|
|
BRPI0920743A2
(pt)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
ribonucleases terapeuticas
|
|
WO2010123501A1
(en)
|
2009-04-22 |
2010-10-28 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
|
US10837020B2
(en)
|
2009-04-22 |
2020-11-17 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long RNA molecules
|
|
EP3524275A1
(en)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Innate immune supression enables repeated delivery of long rna molecules
|
|
TWI507525B
(zh)
|
2009-06-26 |
2015-11-11 |
Regeneron Pharma |
具天然免疫球蛋白形式之易分離的雙專一性抗體
|
|
HUE041426T2
(hu)
*
|
2009-11-02 |
2019-05-28 |
Univ Washington |
Terápiás nukleáz-készítmények és eljárások
|
|
EP2507267B1
(en)
|
2009-12-02 |
2016-09-14 |
Acceleron Pharma, Inc. |
Compositions and methods for increasing serum half-life of fc fusion proteins
|
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Kirin Co., Ltd. |
Modified antibody composition
|
|
KR20130070576A
(ko)
|
2010-04-09 |
2013-06-27 |
노보자임스 바이오파마 디케이 에이/에스 |
알부민 유도체 및 변이체
|
|
PT2560993T
(pt)
|
2010-04-20 |
2024-09-16 |
Genmab As |
Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
JP2013537416A
(ja)
|
2010-08-13 |
2013-10-03 |
メディミューン リミテッド |
変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
|
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
WO2012068630A1
(en)
|
2010-11-26 |
2012-05-31 |
The University Of Melbourne |
Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke
|
|
US20120201746A1
(en)
|
2010-12-22 |
2012-08-09 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
TWI529163B
(zh)
|
2011-01-25 |
2016-04-11 |
陶氏農業科學公司 |
用於製備４－胺基－５－氟－３－鹵素－６－（經取代之）吡啶甲酸酯的方法
|
|
SG191977A1
(en)
|
2011-02-01 |
2013-08-30 |
Genmab As |
Human antibodies and antibody-drug conjugates against cd74
|
|
MX363013B
(es)
|
2011-02-25 |
2019-03-04 |
Recombinetics Inc |
Animales genéticamente modificados y métodos para su obtención.
|
|
CA2832387A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
US20140170148A1
(en)
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
SI3505528T1
(sl)
|
2011-04-21 |
2021-04-30 |
Glaxo Group Limited |
Modulacija izražanja virusa hepatitisa B (HBV)
|
|
CA2834626A1
(en)
|
2011-04-29 |
2012-11-01 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
|
US9862926B2
(en)
|
2011-06-27 |
2018-01-09 |
Cellscript, Llc. |
Inhibition of innate immune response
|
|
US20140178479A1
(en)
|
2011-08-12 |
2014-06-26 |
Perosphere, Inc. |
Concentrated Felbamate Formulations for Parenteral Administration
|
|
WO2013059299A1
(en)
|
2011-10-17 |
2013-04-25 |
The Uab Research Foundation |
Antibodies for interferon subtypes and interferon/interferon receptor ternary complex and uses thereof
|
|
IN2014CN03887A
(enExample)
|
2011-10-27 |
2015-10-16 |
Genmab As |
|
|
US9574010B2
(en)
*
|
2011-11-04 |
2017-02-21 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
JP6351572B2
(ja)
*
|
2012-05-10 |
2018-07-04 |
ザイムワークス，インコーポレイテッド |
Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
CN104603152A
(zh)
|
2012-06-13 |
2015-05-06 |
米迪缪尼有限公司 |
针对抗i型干扰素受体(ifnar)抗体的固定剂量方案
|
|
WO2014004586A1
(en)
*
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
GB2503883A
(en)
|
2012-07-09 |
2014-01-15 |
King S College London |
Variant IgE with reduced affinity to CD23
|
|
BR112015000798A2
(pt)
*
|
2012-07-13 |
2017-06-27 |
Zymeworks Inc |
heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
US10047167B2
(en)
|
2013-03-15 |
2018-08-14 |
Eli Lilly And Company |
Methods for producing fabs and bi-specific antibodies
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
US9861681B2
(en)
|
2013-04-18 |
2018-01-09 |
The United States of America as represented by the Secretary of the Army, on behalf of the United States Army Medical Research Institute of Infectious Diseases |
Therapeutic compositions for neutralizing type I interferons, and methods of use
|
|
HUE056580T2
(hu)
|
2013-05-30 |
2022-02-28 |
Kiniksa Pharmaceuticals Ltd |
Onkosztatin-M-receptor antigénjét kötõ fehérjék
|
|
EP3004174B1
(en)
|
2013-05-31 |
2019-04-17 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
SI3063275T1
(sl)
|
2013-10-31 |
2020-02-28 |
Resolve Therapeutics, Llc |
Terapevtske fuzije nukleaza-albumin in postopki
|
|
CN113248613B
(zh)
|
2014-01-15 |
2024-08-23 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN结合性质的Fc区变体
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
KR20150140177A
(ko)
|
2014-06-05 |
2015-12-15 |
한미약품 주식회사 |
단백질 및 펩타이드의 면역원성을 감소시키는 방법
|
|
WO2016069889A1
(en)
*
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
|
ES2935274T3
(es)
|
2014-12-05 |
2023-03-03 |
Merck Patent Gmbh |
Anticuerpo con intercambio de dominios
|
|
WO2016087648A1
(en)
|
2014-12-05 |
2016-06-09 |
Universität Für Bodenkultur Wien |
Immunoglobulins with incorporated heterologous ch3 domains resulting in a prolonged half-life
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
CA2984458A1
(en)
|
2015-05-13 |
2016-11-17 |
Zymeworks Inc. |
Antigen-binding constructs targeting her2
|
|
US9693229B2
(en)
|
2015-11-05 |
2017-06-27 |
International Business Machines Corporation |
Logical subscriber identification module (SIM)
|
|
CN107007606B
(zh)
|
2016-02-04 |
2021-10-26 |
南京舒鹏生物科技有限公司 |
一种用于干燥综合症预防及治疗的药物及其组合
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
WO2017185177A1
(en)
|
2016-04-25 |
2017-11-02 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
KR102527840B1
(ko)
|
2016-04-29 |
2023-05-03 |
화이자 인코포레이티드 |
인터페론 베타 항체 및 그의 용도
|
|
MA45554A
(fr)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
Fusions de binucléase optimisées.
|
|
HUE065861T2
(hu)
|
2016-08-26 |
2024-06-28 |
Sanofi Sa |
Szelektív könnyûlánc-párosítást elõsegítõ multispecifikus antitestek
|
|
US10072296B2
(en)
|
2016-09-19 |
2018-09-11 |
The Charlotte Mecklenburg Hospital Authority |
Compositions and methods for sjögren's syndrome
|
|
JP6349003B1
(ja)
|
2017-03-17 |
2018-06-27 |
東洋ビーネット株式会社 |
耐熱性ルシフェラーゼ
|
|
CN111315767B
(zh)
|
2017-08-22 |
2025-03-18 |
萨纳生物有限责任公司 |
可溶性干扰素受体及其用途
|
|
CA3124352A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|